#Bioretec #Finland #Tampere #RemeOs #Activa

Summary of Bioretec Ltd's Half-Year Report 2025

On August 14, 2025, Bioretec Ltd provided an overview of its half-year performance, emphasizing growth potential driven by recent financial maneuvers and expanding market reach. The company successfully raised EUR 9 million through a rights issue, reflecting strong investor confidence in its strategic direction and innovative product range.

Financial Overview

Q2 Highlights

During the second quarter of 2025, Bioretec recorded net sales of EUR 665,000, a significant decline of 51.7% compared to EUR 1,379,000 during the same period in 2024. This reduction is largely attributed to a one-time credit related to the conclusion of a U.S. pilot distribution agreement and a transition from stocking distributors to direct sales partners in the U.S. Despite the decrease, direct market growth remains strong, particularly for its Activa product line in China and the momentum for the RemeOs products.

Half-Year Performance

For the first half of the year, Bioretec's net sales rose slightly to EUR 2,062,000, a marginal increase over EUR 2,061,000 in 2024. The sales margin, excluding other income, was reported at 49.3%, down from 70.4% the previous year, indicating increased costs linked to materials and services. The overall profit loss for this period was EUR -4,801,000, up significantly from EUR -1,884,000 a year before, reflecting higher operational and development costs associated with ongoing product innovations.

Key Developments

The first half of 2025 marked a notable period of change for Bioretec, particularly in leadership. Following the departure of CEO Alan Donze, Sarah van Hellenberg Hubar-Fisher has stepped in as the interim CEO, effective May 15, 2025. Alongside her appointment, Mirva Ekman took on the role of Quality Director, reinforcing the management team during this transitional period.

In June 2025, Bioretec executed a rights issue, offering existing shareholders the chance to purchase up to 6,156,618 new shares. The swift oversubscription of this offering—raising approximately EUR 9.2 million—illustrates the robust support from investors who recognize the company’s vision for expansion in the orthopedics market. The rights issue allowed Bioretec to increase its total shares from 24,626,474 to 30,783,092.

Market Strategy and Product Pipeline

As part of its strategic initiatives, Bioretec is refocusing its operations to optimize market access and operational efficiency. The successful launch of sterile, single-use instruments to complement the Activa cannulated screw signifies this shift, aimed at enhancing operational standards and addressing infection control preferences among U.S. healthcare providers. In addition, key product developments are underway, including the 510(k) submissions for RemeOs and clinical trials for new innovative products.

The first surgeries involving the RemeOs Trauma Screw in Europe not only mark a significant milestone in product commercialization but also establish the groundwork for a global market presence moving forward. As Bioretec continues to build its distribution network and strengthen its sales approach, it is well-positioned for accelerated growth in the orthopedics sector.

Conclusion

Looking ahead, Bioretec Ltd remains committed to refining its operational strategies while developing its innovative product offerings. The company's focus on growth through effective capital utilization and market responsiveness aims to yield increased shareholder value and positively impact patient care.

Bioretec is committed to redefining the orthopedic landscape with its pioneering absorbable implant technologies that promise sustainable and efficient healing solutions.

For further details, the complete half-year report with tables is available at Bioretec's investor relations page.

Website: Bioretec Investor Relations